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American Industry
and the U.S. Cardiovascular
Clinical Research Enterprise
An Appropriate Analogy?*
Robert M. Califf, MD,†‡
Robert A. Harrington, MD‡§
Durham, North Carolina
The report by Kim et al. (1) in this issue of the Journal
documents the increasingly widespread phenomenon of the
“offshoring” of clinical research—in this case, clinical trials
conducted in foreign countries despite being funded by U.S.
taxpayers, administered through grants and contracts from
the National Heart, Lung, and Blood Institute (NHLBI),
and intended to inform American practice decisions. This
report is 1 of a number of recent reports that raise the
question of whether American clinical research, like many
other U.S. industries, has become so expensive and ineffi-
cient that it is no longer a viable competitive enterprise
within our borders.
See page 671
Clinical research provides the quantitative evidence that
consumers, patients, health care providers, and payers need
to weigh risks and benefits when making decisions about
medical care. Unfortunately, there is a dearth of high-
quality evidence to support such decision making. Even in
cardiovascular medicine, which has one of the most sub-
stantial evidence bases among specialties, only a relatively
paltry 15% of guideline recommendations are supported by
findings from definitive randomized trials (2). The widening
gap between our need for high-quality evidence and our
capacity to produce it is increasingly manifest. The way to
bridge this gap, however, is less obvious: should we attempt
to improve U.S. performance in clinical research conduct,
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savings, or both?
When an intervention is evaluated outside the environ-
ment in which it will ultimately be used, the results achieved
in practice may differ from those observed in trials. Recent
U.S. Food and Drug Administration data show that when
multiregional clinical trials are conducted, the magnitude of
the treatment effect is often smaller for U.S. volunteers
compared with participants randomized abroad (3). The
reasons for this are not entirely clear, but genetics, practice
patterns (including the use of concomitant medications and
procedures), environment, culture (including diet), health
care system structure, and the play of chance all likely
contribute to the phenomenon.
We also note that clinical research creates attractive,
high-paying jobs. Given the current U.S. economic climate,
the realization that through National Institutes of Health
(NIH) funding, American tax revenues are supporting the
export of good jobs abroad may prove economically and
politically unattractive.
Nevertheless, we strongly believe that the globalization of
clinical research is a powerful social good (4) when it stems
from a universal need for collaborative research that informs
each country’s practice and reflects the biology of relevant
populations. But when research is offshored predominantly
because the U.S. enterprise has become incapable of con-
ducting it efficiently, we must focus our attention on fixing
our own system.
The myriad problems besetting American clinical re-
search are well documented. The system is slow and often
fails to meet recruitment targets. It is more costly than other
systems and suffers from poor quality, as evidenced by high
rates of nonadherence to study protocols and treatments and
trial withdrawal by study participants. Furthermore, there is
no reliable indication that the American system produces
data that are of higher quality or better managed than data
collected outside of the United States. Unsurprisingly,
investigators have become discouraged, and an exodus of
talent has recently ensued (5).
When we consider that clinical research offers cardiovas-
cular specialists the chance to lose money, make their
practices less efficient, incur risks from regulatory infrac-
tions, and contend with reputational problems arising from
involvement with industry, we should not be surprised at
these trends. Only the intellectual excitement, challenge,
and fun of answering critical questions while participating in
advancing knowledge keep the investigator pool at its
current level. From our experience leading an academic
coordinating center for clinical trials, we note that although
there are approximately 5,000 acute care hospitals in the
United States, only about 5% consistently participate in
trials, and 1% account for the vast majority of participant
accrual (L. Berdan, personal communication, February
2011).
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clinical research are plain, the causes underlying the ineffi-
ciencies of our most powerful academic medical centers,
which receive the majority of NIH funding, are more
obscure. While the National Cancer Institute has been
evaluating this problem (6) and the NHLBI has initiated its
own effort (Clinical Research United in Successful Enroll-
ment) to address the issue, we believe the current situation
is actually a predictable by-product of the evolution of
modern American medical schools. When the NIH
emerged as the primary funding engine of global basic
biological research in the postwar era, schools of medicine
focused on building capacity to respond to requirements
imposed by this funding juggernaut. Concurrently, the
profitability of industry-funded clinical research gave rise to
a common assumption that private industry rather than
government could pay for it. Equally important, the con-
cepts of unbiased evidence generation and clinical effective-
ness, as well as the daunting need for larger sample sizes to
reliably detect modest treatment effects, had not yet
emerged (7).
The result of this history is clear to anyone who makes
rounds in our “best” academic medical centers. Little prior-
ity is afforded to clinical research, and faculty members who
do participate in multicenter trials get little academic credit
unless they lead those trials. Furthermore, “indirect” fund-
ing from the NIH is often diverted from infrastructure
needed for clinical research and allocated to support discov-
ery science infrastructure. Consequently, there is a prevail-
ing notion among many academic medical centers that
participation in multicenter collaborative investigations con-
stitutes second-tier research.
As with all U.S. health care delivery systems, academic
health and science systems are hard pressed to find
efficiencies, and the clinical enterprise has little tolerance
for slowing practice to accommodate prolonged consent
processes or for deferring profitable procedures. Despite
the widely touted tripartite mission of clinical care,
research, and education, clinical investigators and study
coordinators usually work without support from their
hospital units and clinics; in fact, the relationship is often
adversarial, because the clinical care enterprise regards
research as impeding efficiency and thus threatening its
profitability.
Several critical misconceptions underlie this systemic
failure. Previously, the large profits produced by cardio-
vascular practices meant that the NIH could count on
significant cost sharing for clinical research; conse-
quently, NIH funding often fails to adequately reimburse
costs. Presently, however, while the hospital-facility side
of U.S. cardiovascular medicine is profitable, the physi-
cian– clinical delivery side breaks even at best. And
because salaries are flat or declining, there are no excess
monies for cost sharing.
Another canard is the idea that a portfolio including
industry-sponsored research can ameliorate these fundinggaps. However, industry understandably funds trials most
likely to provide a return on investment and thus is likely to
explore questions that differ from those posed by trials
designed to investigate issues relevant to the public health.
Additionally, industry-funded trials, which frequently in-
volve contract research organizations, have largely shifted
away from academic centers and toward the private setting
to avoid challenges in dealing with the complexities of the
former.
Finally, there is a widely held view among leading
academic centers that clinical research should not need
institutional support. Before the modern clinical trials era,
when clinical research was typically a small-shop enterprise
or even a hobby for interested clinicians, this view might
have been justifiable. However, increasingly sophisticated
trial methodologies, along with a regulatory regime requir-
ing extensive infrastructure and imposing substantial pen-
alties for failure to ensure quality in data acquisition, data
analysis, or protection of research participants, have made
clinical research a professional activity and no longer a
pastime for hobbyists.
Recognizing that this problem is endemic across special-
ties and disease areas, former NIH director Elias Zerhouni
wisely created the Clinical and Translational Science
Awards to provide a home for clinical and translational
researchers within academic health and science systems (8).
ut despite a commitment of $500 million per year, as well
s considerable effort and significant progress in other areas
f translation (9,10), there is as yet no evidence that clinical
esearch has become more efficient. We hope the decision to
lace the Clinical and Translational Science Awards under
he new National Center to Advance Translational Science
ignals an intent to hold academic health and science
ystems accountable for prioritizing the conduct of efficient
linical trials that generate the medical evidence American
roviders, patients, and policy makers need to make rational
ealth care decisions.
The NHLBI has an opportunity to lead the way toward
future in which the U.S. clinical research system, instead
f becoming an obstacle to be circumvented, participates
ully in global efforts to produce relevant, high-quality
vidence to guide cardiovascular clinical practice. We sug-
est the following measures:
. Separate payment for the proper recruitment, consent,
and enrollment of research participants and for the
collection of high-quality research data from funding for
research design and analysis. These activities entail
different skills, and rewarding the latter while marginal-
izing the former (11) will ensure further deterioration of
our capacity and accelerate the offshoring of vital re-
search.
. Ensure that institutions are rewarded separately for
these 2 functions in terms of recognition and academic
acclaim as well as funding. Importantly, NIH funding
is increasingly segregated into “haves” and “have-
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basal infrastructures needed to compete in discovery
science. If funding is allocated for site-based research,
which does not require this infrastructure, the “have-
nots” should be able to compete effectively for NIH
funding within this system, thereby allowing the
development of a group of committed sites, investiga-
tors, and study coordinators while also providing
resources to build systems enabling recruitment, data
collection, and quality assurance.
. Develop networked coordinating centers devoted to
the improvement of research across multiple sites,
along with the design and analysis of multicenter
trials. These centers should be required as a condition
of funding to develop and sustain methods of collab-
oration with other coordinating centers and with
site-based research organizations. This will necessitate
an investment in technological tools, including those
afforded by social networking, to encourage and foster
these collaborations.
. Participate vigorously with other NIH institutes to
solve general administrative issues through the Na-
tional Center to Advance Translational Science. The
imperatives to address excessive delays in institutional
review board review and contract approval, clarify
billing issues and management of indirect costs, and
develop common metrics for quality and efficiency in
research are not disease specific, and common solu-
tions customized to suit special needs will likely prove
effective. This would entail working with U.S. De-
partment of Health and Human Services to develop
smoother collaboration among federal organizations
and agencies, most particularly the Food and Drug
Administration, which has regulatory oversight of
industry-sponsored clinical research.
. Incorporate clinical research within the learning
health system, so that evidence generation becomes
integral to the culture of clinical practice. This effort,
which should be led by the NHLBI, would use
electronic health records and registries as the primary
substrates for data collection, significantly enhancing
efficiency and reducing costs to systems burdened by
redundant data systems and procedures. In addition to
reducing reliance on clinical data reentry into research
records, it should markedly reduce costly on-site
monitoring visits, because data quality can be reviewed
centrally using statistical outlier detection and process
control.
This report by Kim et al. (1) represents a wake-up call. If
e fail to heed it, we may see the U.S. clinical research
nterprise go the way of so many other American industries:
ost to more efficient overseas competitors. Such an outcome
ould be more than an economic disaster. It would also
eprive the American public of relevant, high-quality evi-
ence essential for making appropriate decisions aboutealth care. But if we do succeed in an essential transfor-
ation of the clinical research system, we can renew a
radition of innovation and leadership while participating in
ritical global efforts to better understand the prevention
nd treatment cardiovascular disease around the world
12,13).
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